Belite Bio, Inc
tinlarebant
Stargardt disease type 1
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews tinlarebant for Stargardt disease type 1 around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 13h ago
“The FDA has granted Breakthrough Therapy Designation (BTD), which was granted by the FDA due to the high unmet need among patients living with STGD1.”